Literature DB >> 19009651

Metabolism for cyclosporin A during liver regeneration after partial hepatectomy in rats.

Shigeki Nagayoshi1, Yujo Kawashita, Susumu Eguchi, Yukio Kamohara, Mitsuhisa Takatsuki, Shungo Miyamoto, Satoshi Mochizuki, Akihiko Soyama, Hirotaka Tokai, Masaaki Hidaka, Yoshitsugu Tajima, Takashi Kanematsu.   

Abstract

AIM: To elucidate the metabolism and the effect of the cyclosporin A (CyA) as a representative immunosuppressive drug used in transplantation in a partially hepatectomized rat model.
METHODS: CyA was administered to rats that underwent a 70% hepatectomy. These rats were randomly assigned into three groups according to the dose of CyA administration as follows; (group 1) water, (group 2) 5 mg/kg CyA, (group 3) 10 mg/kg CyA. On postoperative days-1, 3, 7 and 14, the rats were killed to analyze the serum concentration of CyA, the liver regeneration ratio, biochemical or histological markers, and mRNA expression using reverse transcriptase-polymerase chain reaction method to determine albumin and cytochrome p450 expression.
RESULTS: The serum concentration of CyA in group 3 was significantly higher than group 2 during liver regeneration. CyA enhanced the liver regeneration in a dose dependent manner. The mRNA expression associated with CyA metabolism was significantly decreased on day 14, while preserving the albumin producing activity.
CONCLUSION: These data indicate that the p-450 activity required to metabolize the CyA may be reduced during regeneration of the remnant liver after a hepatectomy, which may, therefore, be linked to difficulty in controlling the optimal dose of CyA during early period of LDLT.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 19009651      PMCID: PMC2766117          DOI: 10.3748/wjg.14.6355

Source DB:  PubMed          Journal:  World J Gastroenterol        ISSN: 1007-9327            Impact factor:   5.742


  15 in total

1.  Cyclosporin A: an immunosuppressive agent preferentially active against proliferating T cells.

Authors:  D J White; A M Plumb; G Pawelec; G Brons
Journal:  Transplantation       Date:  1979-01       Impact factor: 4.939

2.  Mode of action of cyclosporin A: a new immunosuppressive agent.

Authors:  D J White; R Y Calne; A Plumb
Journal:  Transplant Proc       Date:  1979-03       Impact factor: 1.066

3.  Cyclosporin A and dexamethasone suppress T cell responses by selectively acting at distinct sites of the triggering process.

Authors:  E L Larsson
Journal:  J Immunol       Date:  1980-06       Impact factor: 5.422

4.  Effects of cyclosporin A on human granulopoiesis in vitro.

Authors:  A Hellman; J M Goldman
Journal:  Transplantation       Date:  1980-11       Impact factor: 4.939

5.  Augmentative effect of cyclosporin A on rat liver regeneration: influence on hepatocyte growth factor and transforming growth factor-beta(1).

Authors:  Y Morii; K Kawano; Y I Kim; M Aramaki; T Yoshida; S Kitano
Journal:  Eur Surg Res       Date:  1999       Impact factor: 1.745

6.  Sex difference in induction of hepatic CYP2B and CYP3A subfamily enzymes by nicardipine and nifedipine in rats.

Authors:  Yoshihiro Konno; Masashi Sekimoto; Kiyomitsu Nemoto; Masakuni Degawa
Journal:  Toxicol Appl Pharmacol       Date:  2004-04-01       Impact factor: 4.219

7.  Indocyanine green clearance and ammonia tolerance in partially hepatectomized and hepatic devascularized, anesthetized dogs.

Authors:  K W Prasse; D E Bjorling; R A Holmes; L M Cornelius
Journal:  Am J Vet Res       Date:  1983-12       Impact factor: 1.156

8.  Liver regeneration and lymphocyte activation.

Authors:  A Sakai; R Pfeffermann; S L Kountz
Journal:  Surg Gynecol Obstet       Date:  1976-12

Review 9.  Liver transplantation: an update 2007.

Authors:  Adnan Said; Michael Einstein; Michael R Lucey
Journal:  Curr Opin Gastroenterol       Date:  2007-05       Impact factor: 3.287

Review 10.  Developments in liver transplantation.

Authors:  R Pichlmayr; P Neuhaus; B Ringe; K Wonigeit; M Burdelski; L Verner; W Lauchart; F W Schmidt
Journal:  Jpn J Surg       Date:  1985-11
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.